Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
X4 Pharmaceuticals, Inc (XFOR)
A forensic read on X4 Pharmaceuticals, Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
0.9
Distress distance
Watch
Earnings quality
5
Forensic signals
-3.9
P / E (ttm)
-42.5%
ROE
$424M
Market cap
0.00%
Dividend yield
150.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
X4 Pharmaceuticals, Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 0.9, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by shareholder returns — halted.
What the filings flag
stopped
FY2021→FY2023
Shareholder returns — halted.Capital returns have STOPPED — $2M of buybacks + dividends in FY2021, but ~$0 in FY2023. A halt usually means the company is conserving cash.
-$313.0M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $217.8M against operating cash flow of -$313.0M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed -33% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw -12.7%/yr figure isn't a real buyback/dilution read here.
66% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 66% of revenue in FY2025 — about $0.10 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 20.7% a year and is falling.
$10M
FY2021–FY2021
Goodwill impairments.Took $10M of goodwill writedowns across 1 year (FY2021 ($10M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$6.5M
Revenue Growth YoY+150.0%
Net Margin-1218.4%
Free Cash Flow-$85.6M
Return on Equity-42.5%
Debt / Equity0.40x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from X4 Pharmaceuticals, Inc's actual 10-K/10-Q/8-K filings?